On a relative basis, the stock has outperformed the S&P 500 by 2.74% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.27% in the last 1 week, and is up 4.39% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -82.59% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $116.75 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $14.76 and the 200 Day Moving Average price is recorded at $18.53.
The stock has recorded a 20-day Moving Average of 6.71% and the 50-Day Moving Average is 3.09%.
Clovis Oncology (NASDAQ:CLVS): stock turned positive on Friday. Though the stock opened at $14.67, the bulls momentum made the stock top out at $14.98 level for the day. The stock recorded a low of $14.29 and closed the trading day at $14.73, in the green by 0.20%. The total traded volume for the day was 680,795. The stock had closed at $14.7 in the previous days trading.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Executive VP and CFO) of Clovis Oncology, Inc., Mast Erle T had sold 3,000 shares worth of $312,540 in a transaction dated November 2, 2015. In this transaction, 3,000 shares were sold at $104.18 per share.
Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.